O'Meara Connor H, Nguyen Thanh Vinh, Jafri Zuhayr, Boyer Michael, Shonka David C, Khachigian Levon M
Department of Otorhinolaryngology, Head & Neck Surgery, The Canberra Hospital, Garran, ACT 2605, Australia.
ANU School of Medicine, Australian National University, Canberra, ACT 0200, Australia.
Nanomaterials (Basel). 2023 Dec 19;14(1):6. doi: 10.3390/nano14010006.
Advanced head and neck cancer (HNC) is functionally and aesthetically destructive, and despite significant advances in therapy, overall survival is poor, financial toxicity is high, and treatment commonly exacerbates tissue damage. Although response and durability concerns remain, antibody-based immunotherapies have heralded a paradigm shift in systemic treatment. To overcome limitations associated with antibody-based immunotherapies, exploration into de novo and repurposed small molecule immunotherapies is expanding at a rapid rate. Small molecule immunotherapies also have the capacity for chelation to biodegradable, bioadherent, electrospun scaffolds. This article focuses on the novel concept of targeted, sustained release immunotherapies and their potential to improve outcomes in poorly accessible and risk for positive margin HNC cases.
晚期头颈癌(HNC)在功能和美观方面具有破坏性,尽管治疗取得了重大进展,但总体生存率较低,经济毒性较高,且治疗通常会加剧组织损伤。尽管仍存在疗效和持久性方面的问题,但基于抗体的免疫疗法已在全身治疗方面引发了范式转变。为了克服与基于抗体的免疫疗法相关的局限性,对全新和重新利用的小分子免疫疗法的探索正在迅速扩展。小分子免疫疗法还具有与可生物降解、生物粘附的电纺支架螯合的能力。本文重点关注靶向、缓释免疫疗法的新概念及其在难以触及且切缘阳性风险高的头颈癌病例中改善治疗效果的潜力。